喹硫平与奋乃静治疗老年精神分裂症对照研究  

Comparative study of quetiapine vs.perphenazine in the treatment of senile schizophrenia

作　　者：毕旭军[1] 杜宇峰[1] 戚万华[1] 李永超[1] 

机构地区：[1]上海市杨浦区精神卫生中心,200090

出　　处：《精神医学杂志》2012年第1期43-44,共2页Journal of Psychiatry

摘　　要：目的评价喹硫平与奋乃静治疗老年精神分裂症的临床疗效和不良反应。方法对196例老年精神分裂症患者随机分为两组,分别服用喹硫平和奋乃静,疗程12周。采用阳性与阴性症状量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)及实验室检查评价不良反应。结果喹硫平组显效率为68.4%,有效率为89.8%,奋乃静组显效率为66.3%,有效率为87.8%,两组差异无显著性;与治疗前相比喹硫平组阴性症状评分于治疗4周起显著降低(P<0.01);治疗12周喹硫平组阴性症状评分低于奋乃静组(P<0.05)。结论喹硫平对老年精神分裂症疗效较好,尤其是阴性症状,且不良反应少。Objective To evaluate the efficacy and safety of quetiapine and perphenazine for senile patients with schizophrenia. Methods A total of 196 senile patients with schizophrenia were randomly divided into quetiapine group （n = 98 ） and perphenazine group （n = 98 ） for 12-week treatment. They were assessed with Positive and Negative Symptoms Scale （PANSS）, Treatment Emergent Symptom Scale （TESS） and laboratory examinations to evaluate the efficacy and side effects. Results There were no significant differences between quetiapine group and perphenazine group in markedly improved rate （68.4% vs. 66.3% ） and response rate （89.8% vs. 87.8% ）. Compared with the baseline, scores of negative symptoms in quetiapine group decreased significantly from the 4th week of the treatment （ P 〈0.01 ）. At the end of the treatment,scores of negative symptoms in quetiapine group was significantly lower than that in perphenazine group （P 〈 0.05）. Conclusion Quetiapine has fewer side effects and is more effective in treatment of senile schizophrenia, especially for negative symptoms.

关 键 词：喹硫平 奋乃静 老年 精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]